

Another first for FarmaForce and for Australia

Australia's premium contract pharmaceutical sales organisation proposing to list on the ASX

Dear iQnovate shareholders and friends,

iQnovate Ltd (NSX: IQN, GXG: IQN, OTCQB: IQNDY) made a market announcement today with regard to listing its wholly owned subsidiary "FarmaForce Pty Ltd".

The iQnovate Board has resolved to float its wholly owned pharmaceutical contract sales subsidiary, FarmaForce Pty Ltd (FarmaForce), via a new proposed ASX listing. The Company has committed to an IPO of FarmaForce and listing on the ASX by the end of the 3rd quarter 2015.

The preliminary market research has indicated significant demand for this raising and the proposed offer is anticipated to be oversubscribed.

The Chief Executive Officer of iQnovate, Dr George Syrmalis, said: "FarmaForce is Australia's most innovative pharmaceutical sales organisation currently engaging in deals with multinational pharmaceutical companies. The company's growth since inception has been remarkable and a listing on the ASX will provide a platform for further corporate growth".

FarmaForce is a contract sales organisation catering to the Australian Pharmaceutical Industry. FarmaForce provides sales force solutions to pharmaceutical companies ranging from the provision of supported or syndicated sales teams through to the implementation of complete dedicated national sales forces. FarmaForce's value proposition is to improve operational efficiency and outcomes, optimise life cycle management and return on investment, hedge risk and reduce infrastructure costs for its clients.

iQnovate is proud to share this milestone moment with our shareholders and friends. We would like to take this opportunity to thank you all for your ongoing support.

Click [here](#) view the market announcement.

If you have any queries about the announcement, please contact our Investor Relations team investor.relations@iqnovate.com on +61 2 8239 5400.

Safe Harbor Statement

Any statements in this press release that relate to the Company's expectations are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act. The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees. Since this information may involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. Additional risks associated with iQnovate's business can be found in its periodic filings with the National Stock Exchange of Australia.

SOURCE

iQnovate Limited

iQnovate Ltd is a life science organisation, providing intellectual property asset management services and scientific advice to the global Biopharmaceutical industry. Whether the asset is a pharmaceutical, medical device, technology platform or a compound in development, iQnovate will effectively manage your asset through its complete life cycle, from clinical trials right through to maturity. iQnovate clients are pharmaceutical, biotechnology, medical device companies as well as financial institutions, academic and government organisations

Sydney: 222 Clarence Street, Sydney, NSW 2000, Australia •Phone: +61 2 8239 5400 •Fax: +61 2 8362 9325

New York: 200 Park Avenue, Suite 1700, New York City, NY, USA 10166 •

London: 5 Harbour Exchange, Harbour Exchange Square, Canary Wharf E14 9GE UK•